Mahajan, A., Tomasi, A., Sparks, M. A., Whittelsey, M., LaChance, A., & Sparks, J. A. (2026). Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis. Rheumatology (Oxford), 65(1). https://doi.org/10.1093/rheumatology/keaf693

Mahajan, Arjun, Alessandra Tomasi, Matthew A. Sparks, Maureen Whittelsey, Avery LaChance, and Jeffrey A. Sparks. “Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis.” Rheumatology (Oxford) 65, no. 1 (January 8, 2026). https://doi.org/10.1093/rheumatology/keaf693.

Mahajan A, Tomasi A, Sparks MA, Whittelsey M, LaChance A, Sparks JA. Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis. Rheumatology (Oxford). 2026 Jan 8;65(1).

Mahajan, Arjun, et al. “Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis.” Rheumatology (Oxford), vol. 65, no. 1, Jan. 2026. Pubmed, doi:10.1093/rheumatology/keaf693.

Mahajan A, Tomasi A, Sparks MA, Whittelsey M, LaChance A, Sparks JA. Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis. Rheumatology (Oxford). 2026 Jan 8;65(1).